Genesis Therapeutics

Genesis Therapeutics is an AI-based platform for discovering drugs. It uses advanced molecular AI to identify previously inaccessible protein targets, explore chemical possibilities, and speed up the creation of new medications.

The company's platform integrates state-of-the-art methods like 3D spatial graph modeling and molecular simulation for the development of breakthrough drug prospects. Genesis Therapeutics, staffed by seasoned drug developers, machine learning specialists, and software engineers, is dedicated to using AI in biochemistry to find and create treatments for individuals with serious illnesses. Genesis Therapeutics seeks to transform the biotechnology and drug discovery industries with its sophisticated AI.

The company has gained considerable media attention and significant funding, including a recently concluded $200 million Series B funding round that was oversubscribed. Genesis Therapeutics has also forged strategic alliances with major industry players like Eli Lilly, Roche, and Genentech, demonstrating the recognition and support it has garnered from within the biotech sector. Overall, Genesis Therapeutics is a leading firm in the field of AI-driven drug discovery. It employs cutting-edge methods and partnerships to expedite the creation of crucial new medications for the benefit of patients across the globe.